Neurotrope, Inc.
Neurotrope, Inc. (NTRP): 1 pipeline candidate · ~26 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
25.5 months
0% dilution
Lead: Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Neurotrope, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$30.4M
Cash
$27.0M
Quarterly Burn
$3.3M
Runway
25.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| bryostatin-1 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
12
Total value held
$3.7M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 675,117 | $2.2M |
| vanguard capital management llc | 254,636 | $828K |
| geode capital management, llc | 122,635 | $399K |
| vanguard fiduciary trust co | 58,459 | $190K |
| northern trust corp | 12,493 | $41K |
| group one trading llc | 47 | $153 |
| physician wealth advisors, inc. | 20 | $65 |
| wealth preservation advisors, llc | 15 | $49 |
| caitong international asset management co., ltd | 3 | $10 |
| harbour investments, inc. | 3 | $10 |
Showing top 10 of 12 institutional holders of Neurotrope, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Neurotrope, Inc.'s pipeline?
Neurotrope, Inc. (NTRP) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Neurotrope, Inc.'s lead drug candidate?
Neurotrope, Inc.'s most advanced tracked candidate is bryostatin-1 (Phase 2) for Alzheimer's disease.
What is Neurotrope, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Neurotrope, Inc. has approximately 25.5 months of cash runway.
What is Neurotrope, Inc.'s market capitalization?
Neurotrope, Inc.'s market capitalization is approximately $30.4M.
Who is the CEO of Neurotrope, Inc.?
Mr. William Kerby is the chief executive officer of Neurotrope, Inc. (NTRP).
Get the full picture on Neurotrope, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.